157
Registered trials
54
Recruiting
92
Completed trials
85
Sponsors
26
Countries
Phase III:
51
Phase II/III:
3
Phase II:
79
Phase I/II:
13
Phase III/IV:
2
Phase IV:
5
Phase I (Other):
3
Other:
1
Oversight events:
4 serious breaches
9 temporary halts
1 urgent safety measure
1 unexpected event
2 corrective measures
across 10 trials
View oversight register →
Indications tested
Non-small cell lung cancer
14
Non-small cell lung cancer stage III
9
Small cell lung cancer extensive stage
7
Cholangiocarcinoma
6
Triple negative breast cancer
5
Small cell lung cancer
4
Hepatocellular carcinoma
4
Non-small cell lung cancer metastatic
3
Non-small cell lung cancer stage IIIB
3
Bladder cancer
3
Non-small cell lung cancer stage IIIA
3
Non-small cell lung cancer stage II
3
Sponsors using this IMP
AstraZeneca AB
48
Unicancer
8
ETOP IBCSG Partners Foundation
4
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
4
Institut Jules Bordet
3
Intergroupe Francophone De Cancerologie Thoracique
3
Merck Sharp & Dohme LLC
3
Amgen Inc.
2
Amsterdam UMC Stichting
2
Astrazeneca Farmaceutica Spain S.A.
2
Centre Leon Berard
2
F. Hoffmann-La Roche AG
2
All trials — page 6
157 totalShowing 121–144 of 157 trials